Anika Therapeutics (ANIK) Income from Continuing Operations (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Income from Continuing Operations of 3280000.0 for Q2 2026, up 170.3% year-over-year from 1213485.57 in Q2 2025, and up 164.87% quarter-over-quarter from 5056000.0 in Q1 2026.
Anika Therapeutics (ANIK) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Income from Continuing Operations for 17 consecutive years, with 3280000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 170.3% year-over-year to 3280000.0; the TTM figure through Jun 2026 stood at 1464000.0 (up 89.77% YoY), while the FY2025 annual figure was 8293000.0, up 18.23% from the prior year.
- Income from Continuing Operations advanced to 3280000.0 in Q2 2026 per ANIK's latest filing, from 5056000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 16184000.0 in Q4 2023 and bottomed at 10314000.0 in Q1 2023.
- Historically, Income from Continuing Operations has averaged 1306888.89 across 5 years, with a median of 2875500.0 in 2022.
- On a YoY basis, Income from Continuing Operations climbed as much as 411.38% in 2022 and fell as far as 853.99% in 2022.
- Anika Therapeutics' Income from Continuing Operations stood at 10070000.0 in 2022, then surged by 60.71% to 16184000.0 in 2023, then plunged by 123.48% to 3800000.0 in 2024, then jumped by 191.76% to 3487000.0 in 2025, then declined by 5.94% to 3280000.0 in 2026.
- Business Quant data shows ANIK's Income from Continuing Operations at 3280000.0 in Q2 2026, 5056000.0 in Q1 2026, and 3487000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 285.86 Mn | 247.45 Mn | 21.24 Mn | 3.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.28 Mn |
| Mar 31, 2026 | -5.06 Mn |
| Dec 31, 2025 | 3.49 Mn |
| Sep 30, 2025 | -3.18 Mn |
| Jun 30, 2025 | -4.67 Mn |
| Mar 31, 2025 | -3.97 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Sep 30, 2024 | -1.88 Mn |
| Jun 30, 2024 | -2.54 Mn |
| Mar 31, 2024 | -1.96 Mn |
| Dec 31, 2023 | 16.18 Mn |
| Sep 30, 2023 | -6.54 Mn |
| Jun 30, 2023 | -2.74 Mn |
| Mar 31, 2023 | -10.31 Mn |
| Dec 31, 2022 | 10.07 Mn |
| Sep 30, 2022 | -4.16 Mn |
| Jun 30, 2022 | -2.84 Mn |
| Mar 31, 2022 | -2.91 Mn |
| Dec 31, 2021 | -3.23 Mn |
| Sep 30, 2021 | 552,000.00 |